{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:31:43Z","timestamp":1792009903581,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67843-8","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T10:02:09Z","timestamp":1721815329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)"],"prefix":"10.1038","volume":"14","author":[{"given":"Pitchumani","family":"Sivakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Saul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay E.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta B.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"issue":"Suppl 1","key":"67843_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/liv.13637","volume":"38","author":"L Serfaty","year":"2018","unstructured":"Serfaty, L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int. 38(Suppl 1), 52\u201355 (2018).","journal-title":"Liver Int."},{"issue":"4","key":"67843_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000375353","volume":"33","author":"S Traussnigg","year":"2015","unstructured":"Traussnigg, S. et al. Challenges and management of liver cirrhosis: practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH. Dig. Dis. 33(4), 598\u2013607 (2015).","journal-title":"Dig. Dis."},{"key":"67843_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-2128-8_1","volume":"2455","author":"S Giashuddin","year":"2022","unstructured":"Giashuddin, S. & Alawad, M. Histopathological diagnosis of nonalcoholic steatohepatitis (NASH). Methods Mol. Biol. 2455, 1\u201318 (2022).","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"67843_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41401-022-00874-x","volume":"43","author":"XF Tong","year":"2022","unstructured":"Tong, X. F. et al. Histological assessment based on liver biopsy: The value and challenges in NASH drug development. Acta Pharmacol. Sin. 43(5), 1200\u20131209 (2022).","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"67843_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100873","volume":"28","author":"D Contreras","year":"2023","unstructured":"Contreras, D. et al. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis. Ann. Hepatol. 28(1), 100873 (2023).","journal-title":"Ann. Hepatol."},{"issue":"4","key":"67843_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s42255-023-00775-1","volume":"5","author":"O Govaere","year":"2023","unstructured":"Govaere, O. et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nat. Metab. 5(4), 572\u2013578 (2023).","journal-title":"Nat. Metab."},{"key":"67843_CR7","doi-asserted-by":"crossref","unstructured":"Liu, Y., et al. A multi-omics analysis of NASH-related prognostic biomarkers associated with drug sensitivity and immune infiltration in hepatocellular carcinoma. J. Clin. Med. 12(4) (2023).","DOI":"10.3390\/jcm12041286"},{"issue":"9","key":"67843_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203054","volume":"13","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One 13(9), e0203054 (2018).","journal-title":"PLoS One"},{"key":"67843_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101167","volume":"50","author":"V Ajmera","year":"2021","unstructured":"Ajmera, V. & Loomba, R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol. Metab. 50, 101167 (2021).","journal-title":"Mol. Metab."},{"issue":"6","key":"67843_CR10","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/jmri.27703","volume":"54","author":"MA Troelstra","year":"2021","unstructured":"Troelstra, M. A. et al. Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: The Amsterdam NAFLD-NASH Cohort. J. Magn. Reson. Imaging 54(6), 1937\u20131949 (2021).","journal-title":"J. Magn. Reson. Imaging"},{"issue":"4","key":"67843_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 78(4), 693\u2013703 (2023).","journal-title":"J. Hepatol."},{"issue":"4","key":"67843_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100661","volume":"5","author":"EA Brown","year":"2023","unstructured":"Brown, E. A. et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 5(4), 100661 (2023).","journal-title":"JHEP Rep."},{"issue":"8","key":"67843_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): A comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8(8), 714\u2013725 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"67843_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","volume":"10","author":"TT Ross","year":"2020","unstructured":"Ross, T. T. et al. Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems. Cell Mol. Gastroenterol. Hepatol. 10(4), 829\u2013851 (2020).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"4","key":"67843_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jcmgh.2020.07.002","volume":"10","author":"J Lambrecht","year":"2020","unstructured":"Lambrecht, J. & Tacke, F. Acetyl-CoA carboxylase inhibition as a therapeutic tool in the battle against NASH: Hitting more than just one mechanism?. Cell Mol. Gastroenterol. Hepatol. 10(4), 859\u2013861 (2020).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"67843_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","volume":"29","author":"N Alkhouri","year":"2020","unstructured":"Alkhouri, N. et al. GS-0976 (Firsocostat): An investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opin. Investig. Drugs 29(2), 135\u2013141 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"67843_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/cpdd.782","volume":"9","author":"A Bergman","year":"2020","unstructured":"Bergman, A. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A three-part randomized phase 1 study. Clin. Pharmacol. Drug Dev. 9(4), 514\u2013526 (2020).","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"2","key":"67843_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","volume":"26","author":"CW Kim","year":"2017","unstructured":"Kim, C. W. et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: A bedside to bench investigation. Cell Metab. 26(2), 394-406.e6 (2017).","journal-title":"Cell Metab."},{"issue":"6","key":"67843_CR19","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/hep.30097","volume":"68","author":"L Goedeke","year":"2018","unstructured":"Goedeke, L. et al. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology 68(6), 2197\u20132211 (2018).","journal-title":"Hepatology"},{"issue":"10","key":"67843_CR20","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","volume":"27","author":"RA Calle","year":"2021","unstructured":"Calle, R. A. et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials. Nat. Med. 27(10), 1836\u20131848 (2021).","journal-title":"Nat. Med."},{"issue":"3","key":"67843_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056159","volume":"12","author":"NB Amin","year":"2022","unstructured":"Amin, N. B. et al. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): Rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open 12(3), e056159 (2022).","journal-title":"BMJ Open"},{"key":"67843_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4614-4118-2_20","volume":"735","author":"MR Mehan","year":"2013","unstructured":"Mehan, M. R. et al. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. Adv. Exp. Med. Biol. 735, 283\u2013300 (2013).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"67843_CR23","doi-asserted-by":"publisher","first-page":"17147","DOI":"10.1038\/s41598-022-22116-0","volume":"12","author":"J Candia","year":"2022","unstructured":"Candia, J. et al. Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci. Rep. 12(1), 17147 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"67843_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate\u2014A practical and powerful approach to multiple testing. J. Royal Stat. Society Series B-Stat. Methodol. 57(1), 289\u2013300 (1995).","journal-title":"J. Royal Stat. Society Series B-Stat. Methodol."},{"issue":"43","key":"67843_CR25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102(43), 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"67843_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1(6), 417\u2013425 (2015).","journal-title":"Cell Syst."},{"issue":"7","key":"67843_CR27","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128(7), 1898\u20131906 (2005).","journal-title":"Gastroenterology"},{"issue":"7","key":"67843_CR28","first-page":"418","volume":"15","author":"S Merat","year":"2012","unstructured":"Merat, S. et al. Sampling error in histopathology findings of nonalcoholic fatty liver disease: A post mortem liver histology study. Arch Iran Med. 15(7), 418\u2013421 (2012).","journal-title":"Arch Iran Med."},{"issue":"10","key":"67843_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. Open 2(10), e1912565 (2019).","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"67843_CR30","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1007\/s10620-021-07089-w","volume":"67","author":"HB Thomaides-Brears","year":"2022","unstructured":"Thomaides-Brears, H. B. et al. Incidence of complications from percutaneous biopsy in chronic liver disease: A systematic review and meta-analysis. Dig. Dis. Sci. 67(7), 3366\u20133394 (2022).","journal-title":"Dig. Dis. Sci."},{"key":"67843_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107352","volume":"134","author":"M Pavlides","year":"2023","unstructured":"Pavlides, M. et al. Liver investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol. Contemp. Clin. Trials 134, 107352 (2023).","journal-title":"Contemp. Clin. Trials"},{"issue":"4","key":"67843_CR32","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jhep.2022.11.028","volume":"78","author":"DGK Rasmussen","year":"2023","unstructured":"Rasmussen, D. G. K. et al. NAFLD and NASH biomarker qualification in the LITMUS consortium\u2014Lessons learned. J. Hepatol. 78(4), 852\u2013865 (2023).","journal-title":"J. Hepatol."},{"issue":"1","key":"67843_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.09.026","volume":"76","author":"KE Corey","year":"2022","unstructured":"Corey, K. E. et al. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. J. Hepatol. 76(1), 25\u201333 (2022).","journal-title":"J. Hepatol."},{"key":"67843_CR34","doi-asserted-by":"crossref","unstructured":"Govaere, O., et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. (2020). 12(572).","DOI":"10.1126\/scitranslmed.aba4448"},{"issue":"1","key":"67843_CR35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1074\/jbc.M806538200","volume":"284","author":"J Terrand","year":"2009","unstructured":"Terrand, J. et al. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J. Biol. Chem. 284(1), 381\u2013388 (2009).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"67843_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCRESAHA.121.318881","volume":"130","author":"S Awan","year":"2022","unstructured":"Awan, S. et al. Wnt5a promotes lysosomal cholesterol egress and protects against atherosclerosis. Circ. Res. 130(2), 184\u2013199 (2022).","journal-title":"Circ. Res."},{"issue":"9","key":"67843_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/1440-1681.12258","volume":"41","author":"L Qin","year":"2014","unstructured":"Qin, L. et al. The novel role and underlying mechanism of Wnt5a in regulating cellular cholesterol accumulation. Clin. Exp. Pharmacol. Physiol. 41(9), 671\u2013678 (2014).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"32","key":"67843_CR38","doi-asserted-by":"publisher","first-page":"16610","DOI":"10.1074\/jbc.M116.717744","volume":"291","author":"AN Hamlin","year":"2016","unstructured":"Hamlin, A. N. et al. LRP1 protein deficiency exacerbates palmitate-induced steatosis and toxicity in hepatocytes. J. Biol. Chem. 291(32), 16610\u201316619 (2016).","journal-title":"J. Biol. Chem."},{"issue":"6","key":"67843_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128903","volume":"10","author":"AP Lillis","year":"2015","unstructured":"Lillis, A. P. et al. LDL receptor-related protein-1 (LRP1) regulates cholesterol accumulation in macrophages. PLoS One 10(6), e0128903 (2015).","journal-title":"PLoS One"},{"key":"67843_CR40","doi-asserted-by":"publisher","first-page":"7902841","DOI":"10.1155\/2018\/7902841","volume":"2018","author":"DT Au","year":"2018","unstructured":"Au, D. T. et al. Macrophage LRP1 promotes diet-induced hepatic inflammation and metabolic dysfunction by modulating Wnt signaling. Mediators Inflamm. 2018, 7902841 (2018).","journal-title":"Mediators Inflamm."},{"key":"67843_CR41","doi-asserted-by":"publisher","first-page":"35282","DOI":"10.1038\/srep35282","volume":"6","author":"E Kumagai","year":"2016","unstructured":"Kumagai, E. et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci. Rep. 6, 35282 (2016).","journal-title":"Sci. Rep."},{"issue":"11","key":"67843_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5(11), 970\u2013985 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"17","key":"67843_CR43","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1073\/pnas.0912059107","volume":"107","author":"J Ecker","year":"2010","unstructured":"Ecker, J. et al. Induction of fatty acid synthesis is a key requirement for phagocytic differentiation of human monocytes. Proc. Natl. Acad. Sci. USA 107(17), 7817\u20137822 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"67843_CR44","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI86610","volume":"126","author":"PL Gordts","year":"2016","unstructured":"Gordts, P. L. et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J. Clin. Invest. 126(8), 2855\u20132866 (2016).","journal-title":"J. Clin. Invest."},{"key":"67843_CR45","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.1038\/srep12931","volume":"5","author":"R Schierwagen","year":"2015","unstructured":"Schierwagen, R. et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci. Rep. 5, 12931 (2015).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67843-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T11:08:57Z","timestamp":1721819337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67843"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67843-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors were Pfizer employees at the time of the work and shareholders of Pfizer Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17072"}}